Interview for mambiznes.pl/ bankier.pl, CEO BRP

„Chcemy, aby Polska w końcu zaistniała na mapie innowacji farmaceutycznych” – Łukasz Zybaczyński, prezes BioResearch Pharma

In recent interview, Łukasz Zybaczyński, CEO o BioResearch Pharma S.A. discussed company’s plans to develop innovative treatments for androgenetic alopecia and psoriasis.

BioResearch Pharma focuses on drug repositioning, which can significantly speed up the drug development process.

BRP-011 project targets androgenetic alopecia, a condition affecting up to 50% of men under 50 and 30-40% of women over 50.

The BRP-007 project aims to treat psoriasis, which affects 1-3% of the global population. We project commercialization after the completion of Phase I clinical trials, which should occur by the end of 2026 for both projects. In our opinion, this is the optimal time to find an industry partner and jointly develop our drugs,” Łukasz Zybaczyński, CEO of BioResearch Pharma S.A.